Bakutrol® is a patented Psoralea corylifolia extract standardized to bakuchiol. Clinically-proven to effectively treat acne and post-inflammatory hyperpigmentation (PIH).
Key Pointers
Indian clinical trial on 50 subjects with acne
Anti-microbial, anti-inflammatory, anti-melanogenic, anti-oxidation activity and tyrosinase inhibition
Effective in inflammatory and non-inflammatory lesions
Promotes clear skin and improves skin tone
Clinically studied in Fitzpatrick skin type 3-6 with no adverse effects
Key Pointers
Indian clinical trial on 50 subjects with acne
Anti-microbial, anti-inflammatory, anti-melanogenic, anti-oxidation activity and tyrosinase inhibition
Effective in inflammatory and non-inflammatory lesions
Promotes clear skin and improves skin tone
Clinically studied in Fitzpatrick skin type 3-6 with no adverse effects
Clinical Findings
Bakutrol™ is clinically validated in 4 clinical trials to effectively treat acne and PIH
Clinically studied in Fitzpatrick skin type 3-6 with no adverse effects
29% reduction in acne-induced PIH in just 4 weeks
58% reduction in inflammatory lesions in 8 weeks
Reduces non-inflammatory lesions as well
43% inhibition in tyrosinase expression and 15% reduction in melanin expression
Potency of Bakutrol™ at 5 μM was equivalent to a well-known melanogenesis inhibitor, Phenylthiourea (PTU) at 10 μM
